Essex Bio-Technology Limited (HKG:1061)
Hong Kong · Delayed Price · Currency is HKD 2.290
+0.020 (0.88%)
Aug 27, 2026, 4:08 PM HKT
Essex Bio-Technology Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,722 | 1,814 | 1,670 | 1,737 | 1,318 | 1,638 | |
Revenue Growth | 0.24% | 8.62% | -3.87% | 31.82% | -19.54% | 67.43% |
Cost of Revenue | 226.42 | 195.92 | 171.15 | 174.94 | 128.38 | 241.89 |
Gross Profit | 1,496 | 1,618 | 1,499 | 1,562 | 1,189 | 1,396 |
Selling, General & Admin | 1,159 | 1,207 | 1,148 | 1,229 | 914.19 | 989.71 |
Other Operating Expenses | -7.65 | -6.3 | -11.44 | -18.51 | -26.83 | 12.24 |
Operating Expenses | 1,152 | 1,201 | 1,144 | 1,210 | 887.36 | 1,002 |
Operating Income | 343.76 | 416.78 | 354.79 | 351.57 | 301.97 | 393.82 |
Interest Expense | -9.64 | -7.82 | -6.09 | -11.21 | -11.47 | -9.22 |
Interest & Investment Income | 14 | 11.83 | 11.45 | 12.34 | 8.88 | 9.86 |
Earnings From Equity Investments | -0 | -0.16 | -2.91 | -1.64 | -0.19 | - |
EBT Excluding Unusual Items | 348.12 | 420.63 | 357.24 | 351.06 | 299.18 | 394.46 |
Impairment of Goodwill | - | - | - | - | -25.83 | - |
Asset Writedown | -8.47 | -8.47 | -2.88 | -5.05 | -13.01 | - |
Legal Settlements | -0.1 | -10.16 | 21.14 | - | - | - |
Other Unusual Items | 12.66 | 12.66 | - | - | - | - |
Pretax Income | 359.06 | 414.66 | 375.5 | 346.01 | 260.34 | 394.46 |
Income Tax Expense | 93.65 | 96.57 | 68.28 | 70.75 | 34.93 | 48.49 |
Net Income | 265.41 | 318.09 | 307.22 | 275.26 | 225.41 | 345.97 |
Net Income to Common | 265.41 | 318.09 | 307.22 | 275.26 | 225.41 | 345.97 |
Net Income Growth | -15.25% | 3.54% | 11.61% | 22.11% | -34.85% | 58.03% |
Shares Outstanding (Basic) | 567 | 567 | 567 | 570 | 574 | 577 |
Shares Outstanding (Diluted) | 567 | 567 | 582 | 596 | 599 | 602 |
Shares Change | -0.41% | -2.63% | -2.24% | -0.62% | -0.43% | -0.21% |
EPS (Basic) | 0.47 | 0.56 | 0.54 | 0.48 | 0.39 | 0.60 |
EPS (Diluted) | 0.47 | 0.56 | 0.53 | 0.47 | 0.38 | 0.58 |
EPS Growth | -15.00% | 5.49% | 13.38% | 22.52% | -34.14% | 55.93% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 218.29 | 198.81 | 324.07 | 318.17 | 293.29 | 319.12 |
Free Cash Flow Per Share | 0.39 | 0.35 | 0.56 | 0.53 | 0.49 | 0.53 |
Dividend Per Share | 0.120 | 0.140 | 0.120 | 0.090 | 0.065 | 0.095 |
Dividend Growth | -7.69% | 16.67% | 33.33% | 38.46% | -31.58% | 90.00% |
Gross Margin | 86.85% | 89.20% | 89.75% | 89.93% | 90.26% | 85.23% |
Operating Margin | 19.96% | 22.98% | 21.25% | 20.24% | 22.92% | 24.05% |
Profit Margin | 15.41% | 17.54% | 18.40% | 15.85% | 17.11% | 21.13% |
Free Cash Flow Margin | 12.68% | 10.96% | 19.41% | 18.32% | 22.26% | 19.49% |
EBITDA | 397.94 | 467.9 | 400.71 | 402.67 | 336.24 | 419.02 |
EBITDA Margin | 23.11% | 25.80% | 24.00% | 23.18% | 25.52% | 25.59% |
D&A For EBITDA | 54.17 | 51.12 | 45.92 | 51.09 | 34.27 | 25.2 |
EBIT | 343.76 | 416.78 | 354.79 | 351.57 | 301.97 | 393.82 |
EBIT Margin | 19.96% | 22.98% | 21.25% | 20.24% | 22.92% | 24.05% |
Effective Tax Rate | 26.08% | 23.29% | 18.18% | 20.45% | 13.42% | 12.29% |